Company: CORT
Filing Date: 2025-07-31
Form Type: 10-Q
Source: 0001628280-25-037005
Chunk: 14

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-07-31
Form: 10-Q
Item: Part I, Item 1
Chunk 14
---
 options, 1.6 million RSAs and less than 0.1 million restricted stock units (“RSUs”) outstanding. As of December 31, 2024, we had 24.7 million stock options, 1.2 million RSAs and less than 0.1 million RSUs outstanding.Stock-based CompensationThe following table summarizes our stock-based compensation by financial statement classification:Three Months Ended June 30,Six Months Ended June 30, 2025202420252024 (in thousands)Capitalized stock-based compensation$107 $83 $251 $128 Cost of sales27 14 63 25 Research and development5,397 4,437 11,718 8,358 Selling, general and administrative13,599 10,756 29,072 20,073 Total stock-based compensation$19,130 $15,290 $41,104 $28,584 

7. Net Income Per Share

We compute our basic and diluted net income per share in conformity with the two-class method required for companies with participating shares. Under the two-class method, net income is determined by allocating net income between common stock and unvested RSAs. We compute basic net income per share by dividing our net income attributable to common stockholders by the weighted-average number of common shares outstanding during the period. We compute diluted net income per share by dividing our net income attributable to common stockholders by the weighted-average number of common shares outstanding during the period, including potentially dilutive stock options and unvested RSUs, less unvested RSAs. We use the treasury stock method to determine the number of dilutive shares of common stock resulting from stock options and unvested RSUs.

15

The following table shows the computation of net income per share for each period:Three Months Ended June 30,Six Months Ended June 30, 2025202420252024 (in thousands, except per share amounts)Numerator:  Net income attributable to common stockholders$34,611 $35,120 $54,918 $62,640 Denominator:Weighted-average shares used to compute basic net income per common share104,111 103,118 104,108 102,954 Dilutive effect of employee stock options and unvested RSUs16,374 8,126 16,119 7,596 Weighted-average shares used